Eli Lilly and Novo Nordisk both beat Q2 estimates and raised their full-year outlooks, but investors favored Lilly, boosting its shares while punishing Novo. Lilly leads the obesity drug market with a 60.9% U.S. share, driven by strong sales of Mounjaro and Zepbound, and raised its revenue guidance amid sustained demand despite pricing pressures. Novo, holding 38.8% market share, also beat expectations but faced investor concerns over its pipeline and growth prospects, especially after mixed trial results and a weaker-than-expected launch of its Wegovy pill. The diverging investor confidence highlights Lilly as the market momentum leader, while Novo works to regain market share and prove its long-term growth strategy.
Nxera Pharma announced a net profit of JPY 1,591 million (US$10.1 million) for Q2 2026, reversing a prior loss due to multiple milestone payments from partners like Neurocrine, AbbVie, and Lilly. The company progressed regulatory approvals and commer...
Eli Lilly reported strong Q2 results with robust revenue growth led by key drugs Mounjaro and Zepbound. The company raised its 2026 revenue guidance to $85–87 billion, supported by volume gains despite price declines, and expects continued margin exp...
Eli Lilly reported a 48% year-on-year revenue increase to $22.97 billion, driven by strong sales of GLP-1 drugs Mounjaro and Zepbound, which make up about 65% of total revenue. The company raised its 2026 revenue guidance to $85 billion–$87 billion, ...
The Dow Jones surged 650 points to a new high of 54,740, and the S&P 500 also reached an all-time high, rising 0.7% to 7,790. However, tech stocks showed weakness with the Nasdaq up only 0.35%, dragged down by a 10% plunge in SpaceX shares after its ...
Eli Lilly reported Q2 revenue of $22.97 billion, up 48% year-over-year, surpassing Wall Street estimates driven by strong sales of Mounjaro and Zepbound weight-loss and diabetes treatments. Non-GAAP EPS rose 33% to $8.38, beating expectations. The co...
